Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Lilly

R&D costs rise as late-stage pipeline advances

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 2Q10

2Q10 Revenues: $5.7 billion (+9%)

2Q10 Earnings: $1.3 billion (+16%)

YTD Revenues: $11.2 billion (+9%)

YTD Earnings: $2.7 billion (+5%)

Comments: Zyprexa revenues were up 5% in 2Q10 and 7% in YTD to $1.3 billion and $2.5 billion, respectively. U.S. sales of the drug were up 10% in 2Q10 to $638 million. Cymbalta revenues were up 17% ($868 million) and 15% ($1.7 billion) during those spans, while Alimta rose 43% ($552 million) and 50% ($1.1 billion) for 2Q10 and YTD. Effient sales were $22.9 million in 2Q10, following an $8.8 million performance in 1Q10. R&D expenses were up 14% in 2Q10 to $1.2 billion and 12% YTD to $2.2 billion. The increase was due to late-stage products and milestone payments.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters